目的 探討?zhàn)ジ羞诜郝?lián)合脾氨肽治療小兒反復(fù)呼吸道感染的臨床療效。方法 選取2015年9月-2016年3月在鄭州市第三人民院治療的反復(fù)呼吸道感染患兒98例，隨機(jī)分為對(duì)照組（49例）和治療組（49例）。對(duì)照組口服脾氨肽口服凍干粉，2 mg/次，1次/d；治療組在對(duì)照組基礎(chǔ)上口服馥感啉口服液，10 mL/次，1~3歲患兒3次/d，4~6歲4次/d，7~12歲5次/d。兩組患兒均經(jīng)過3個(gè)月治療。觀察兩組患兒臨床療效，比較治療前后兩組患兒臨床癥狀改善時(shí)間、血清學(xué)指標(biāo)、白細(xì)胞分類和白三烯D4（LTD4）水平。結(jié)果 治療后，對(duì)照組臨床總有效率為81.63%，顯著低于治療組的95.92%。兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，治療組發(fā)熱、咳嗽和肺部啰音消失時(shí)間均顯著短于對(duì)照組（P<0.05）。治療后，兩組血清IL-1β、IL-6、和腫瘤壞死因子-α（TNF-α）水平均顯著降低，胰島素1號(hào)增長(zhǎng)因子（IGF-1）、干擾素-γ（IFN-γ）和25-OH維生素D₃[25-（OH）D₃]水平均顯著升高，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組上述血清學(xué)指標(biāo)改善程度明顯好于對(duì)照組（P<0.05）。治療后，兩組鼻咽分泌物中中性粒細(xì)胞、嗜酸性粒細(xì)胞和LTD4水平均顯著降低，單核巨噬細(xì)胞顯著升高，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組上述指標(biāo)改善后水平顯著優(yōu)于對(duì)照組（P<0.05）。結(jié)論 馥感啉口服液聯(lián)合脾氨肽治療小兒反復(fù)呼吸道感染可有效改善臨床癥狀，降低炎癥水平，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To evaluate the clinical efficacy of Fuganlin Oral Liquid combined with spleen aminopeptide in treatment of children with recurrent respiratory tract infection. Methods Children (98 cases) with recurrent respiratory tract infection in the Third People's Hospital of Zhengzhou from September 2015 to March 2016 were randomly divided into control (49 cases) and treatment (49 cases) groups. Children in the control group were po administered with Spleen Aminopeptide Oral Lyophilized Powder, 2 mg/time, once daily. Children in the treatment group were po administered with Fuganlin Oral Liquid on the basis of the control group, 10 mL/time, three times daily for 1-3 years old children, four times daily for 4-6 years old children, and five times daily for 7-12 years old children. Children in two groups were treated for 3 months. After treatment, the clinical efficacy was evaluated, and the disappearance time of clinical symptoms, the serological indexes, the leukocyte classification and LTD4 levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 81.63%, which was significantly lower than 95.92% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, the disappearance time of fever, coughing, and lung rale in the treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, the IL-1β, IL-6 and TNF-α levels in two groups were significantly decreased, but IGF-1, IFN-γ and 25-(OH)D₃ was significantly increased, and there were differences in the same group (P < 0.05). And the serological indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the neutrophils, eosinophils and LTD4 levels of nasopharyngeal secretions in two groups were significantly decreased, and the mononuclear macrophage level was significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the improvement levels of these indexes in the treatment group were significantly better than those in the control group (P < 0.05). Conclusion Fuganlin Oral Liquid combined with spleen aminopeptide in treatment of children with recurrent respiratory tract infection can effectively improve the clinical symptoms and reduce the inflammation level, which has a certain clinical application value.